Affordable Access

Publisher Website

MK-0767, a novel dual PPARα/γ agonist, displays robust antihyperglycemic and hypolipidemic activities

Elsevier Inc.
Publication Date
DOI: 10.1016/j.bbrc.2004.04.032
  • Peroxisome Proliferator-Activated Receptor
  • Insulin Sensitizer
  • Hyperglycemia
  • Dyslipidemia
  • Type 2 Diabetes


Abstract Here, we characterize the actions of MK-0767, a dual ligand of the nuclear receptors peroxisome proliferator-activated receptor (PPAR)α and PPARγ. In cell-based assays, MK-0767 produced potent activation of human PPARγ and PPARα with a γ:α potency ratio of ≈2. The dual agonist induced high affinity interactions of PPARα and PPARγ with the transcriptional coactivator CBP in vitro. In ob/ob mice, MK-0767 normalized hyperglycemia and hyperinsulinemia with equal or greater potency and efficacy than pioglitazone. Treatment of hamsters with MK-0767 produced substantial reductions in blood cholesterol and triglycerides. In dogs, MK-0767 reduced serum cholesterol levels with a potency more than 10-fold greater than simvastatin. The efficacies of MK-0767 and simvastatin were additive when given together. We conclude that MK-0767 is a potent dual PPARα/γ agonist with robust insulin sensitizing and hypolipidemic activities.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

MK-0767, a novel dual PPARalpha/gamma agonist, dis...

on Biochemical and Biophysical Re... May 28, 2004

PAR-5359, a well-balanced PPARα/γ dual agonist, ex...

on European Journal of Pharmacolo... Jan 01, 2008

(2R)-2-ethylchromane-2-carboxylic acids: discovery...

on Journal of Medicinal Chemistry Jun 03, 2004

Human pharmacokinetics and interconversion of enan...

on Journal of clinical pharmacolo... March 2007
More articles like this..